Value is attributed to the rise in counterfeit cases and ongoing regulations surrounding anti-counterfeit packaging.
According to The Insight Partners’ new research study on “Anti-Counterfeit Packaging Market Forecast to 2030 – COVID-19 Impact and Global Analysis – by Technology, Application, and Geography,” the anti-counterfeit packaging market size was valued at $159.10 million in 2022 and is expected to reach $435.98 million by 2030; it is also predicted to register a compound annual growth rate (CAGR) of 13.4% from 2022 to 2030. The projected growth of the market is due to the growing demand from the pharma industry, along with increasing cases of counterfeiting and stringent regulations associated with anti-counterfeit packaging, including the Drug Supply Chain Security Act (DSCSA).
Arjo AB, Octane5 International LLC, Antares Vision SpA, CCL Industries Inc, Avery Dennison Corp, The Label Printers LP, KURZ Transfer Products LP, Gestion Groupe Optel Inc, Brady Corp, and Constantia Flexibles International GmbH are among the key parties operating in the global anti-counterfeit packaging market (see table below). These parties focus on strategies, such as investments in research and development activities and new product launches.
Counterfeit pharmaceutical products are fake or unauthorized replicas of genuine medications intentionally mislabeled, adulterated, or substandard in quality. The pharmaceutical industry is particularly vulnerable to counterfeiting due to the high value and demand for medications, complex global supply chains, and the potential for substantial financial gain for counterfeiters.
Understanding the FDA's Exemption for DSCSA Compliance
November 12th 2024In the quest for achieving full traceability, the exemption applies to certain trading partners under the Act, and postpones enforcement of final compliance requirements while acknowledging progress and ongoing challenges.
Is Compounding the Answer to the Semaglutide Shortage? Experts Weigh In
October 30th 2024In this Q&A, Scott Brunner, CEO, and Tenille Davis, Chief Advocacy Officer, of the Alliance for Pharmacy Compounding discuss the challenges faced by patients and healthcare providers due to drug shortages, particularly for semaglutide and other medications.